Price to Operating Profit (P/OP)
since 2005
Paying user area
Try for free
Biogen Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Biogen Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Biogen Inc., P/OP, long-term trends, calculation
| P/OP | = | Share price1, 2, 3 | ÷ | Operating profit per share1 | Operating profit per share1 | = | Income from operations1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 3, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 1, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 2, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 3, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 4, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 5, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 3, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 4, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 3, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Biogen Inc. Annual Report.
- Share Price Trends
- The share price exhibited a general upward trend from 2006 to early 2015, increasing significantly from $45.50 to a peak of $391.12 in 2015. Following this peak, the share price experienced a notable decline, dropping to $220.17 by 2022. This pattern suggests a strong growth phase culminating in 2015, after which market sentiment or other factors contributed to a downward adjustment in the share price over subsequent years.
- Operating Profit Per Share (OPPS) Trends
- Operating profit per share consistently increased over the examined period, rising from $0.69 in 2006 to a peak of $40.46 in 2020. After this peak, the OPPS declined sharply to $19.33 in 2022. This indicates a period of improving operational efficiency and profitability until 2020, followed by a significant reduction in operating profit generation per share during the last years of the data series.
- Price to Operating Profit Ratio (P/OP) Trends
- The P/OP ratio showed substantial fluctuations. Initially, it decreased sharply from 66.33 in 2006 to a low of 8.34 in 2020, suggesting the market valuation became more aligned with operating profits and potentially indicating improved investor confidence or operational performance. However, the ratio increased again to 11.39 by 2022, reflecting a relative increase in share price valuation compared to operating profit or a decrease in operating profits relative to share price.
- Overall Insights
- The data portrays a period of strong growth in both share price and operating profit per share until roughly 2015 to 2020, after which both metrics faced a decline. The P/OP ratio’s decline over most of the period may reflect an improving operational outlook that was recognized by the market. The reversal in share price and operating profit beyond 2020, combined with the rising P/OP ratio, suggests changing market conditions, potentially influenced by business challenges or external economic factors, which impacted profitability and valuation metrics negatively in the recent years.
Comparison to Competitors
Biogen Inc., P/OP, long-term trends, comparison to competitors
| Biogen Inc. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2022 | ||||||||
| Feb 3, 2021 | ||||||||
| Feb 6, 2020 | ||||||||
| Feb 6, 2019 | ||||||||
| Feb 1, 2018 | ||||||||
| Feb 2, 2017 | ||||||||
| Feb 3, 2016 | ||||||||
| Feb 4, 2015 | ||||||||
| Feb 6, 2014 | ||||||||
| Feb 5, 2013 | ||||||||
| Feb 3, 2012 | ||||||||
| Feb 4, 2011 | ||||||||
| Feb 9, 2010 | ||||||||
| Feb 6, 2009 | ||||||||
| Feb 14, 2008 | ||||||||
| Feb 21, 2007 | ||||||||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).